Movella and DIERS Announce 'Free2Move' Healthcare Technology for Objective Patient Assessment

Movella Holdings Inc. (NASDAQ: MVLA) (Movella) (https://www.movella.com/), a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement, today announced a strategic partnership with DIERS, a specialist in medical biomechanics and spine analysis. Together the company will release free²move: a new healthcare technology designed to seamlessly integrate into traditional clinical settings and enable patient testing beyond the limitations of traditional laboratory settings. By providing objective, validated data that meets rigorous healthcare industry standards, this solution enables healthcare professionals to objectively evaluate individuals and achieve more accurate and insightful patient assessments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220855658/en/

Movella and DIERS have joined forces to revolutionize healthcare testing, offering certified protocols and unmatched accuracy. (Photo: Business Wire)

DIERS free²move merges Movella's advanced motion capture technology with DIERS' medical expertise. Central to free²move is the inclusion of the DIERS DICAM software, featuring a range of validated testing protocols. It fulfills and complies with medical requirements of health authorities (Medical Device Regulation-(MDR)) and is also listed with the Food and Drug Administration(FDA). Noteworthy for its emphasis on objective testing, diagnosis, and adherence to treatment protocols, DIERSfree²move introduces a nuanced approach to healthcare technology, prioritizing accuracy and reliability in patient assessment and care.

With more than three decades of experience, DIERS is recognized for its contributions in medical biomechanics, particularly in spine and surface topography analysis. Their expertise extends to various medical applications, including posture analysis and biomechanics in sports.

Carsten Diers, CEO of DIERS International GmbH, said, "Our role is to support professionals in biomechanics and medical biomechanics. With a medical device approved for European and US & Canadian markets, (ISO 13485, EU 2017/745, FDA, CSA), this partnership marks a significant milestone. We can now combine the best in cutting-edge sensor technology with medical knowledge, Reference data and medical guidelines.”